the sun malaysia ipaper logo 150x150
Friday, July 3, 2026
27.5 C
Kuala Lumpur
the sun malaysia ipaper logo 150x150

Using Wolbachia-carrying Aedes mosquitoes to curb dengue cases in N. Sembilan

NILAI: Negeri Sembilan recorded a cumulative 2,824 dengue cases up to the 17th epidemiological week (ME17) this year, compared with 1,032 cases for the same period last year.

State Health, Unity, Information, National Integration and Non-Governmental Organisations Committee chairman Tengku Zamrah Tengku Sulaiman said that using Wolbachia-carrying Aedes mosquitoes is seen as a proactive measure to curb the spike in dengue cases in the state.

She said it uses biological prevention methods, and does not have an impact on human health.

“This method also does not involve the genetic modification of mosquitoes, and does not change the composition of mosquitoes in the natural ecosystem,” she said, at the release of the Wolbachia-carrying Aedes mosquito programme, at the Zone A locality of Desa Anggerik, Nilai, today.

She said Zone A Desa Anggerik is the first locality in the state, selected based on several factors set by the Ministry of Health (MOH), which include number of dengue fever cases, frequency of outbreaks and the high density of Aedes mosquitoes.

Meanwhile, state health director Datuk Dr Harlina Abd Rashid said Negeri Sembilan was selected to expand the Wolbachia-carrying Aedes mosquito release project for the fourth phase of this year.

“To reduce dependence on chemical-based insecticides, the method of releasing Wolbachia-carrying Aedes mosquitoes is seen as a good complementary strategy for dengue vector prevention and control,” she said.

STAY AHEAD OF THE CURVE

Join our community for instant updates and exclusive content.

Join Telegram Channel

Related


spot_img

Latest News

Addressing medical inflation

Consumers are struggling as medical insurance premiums surge, with over 340,000 dropping coverage amid calls for price regulation and stronger public healthcare

Bora Pharmaceuticals Completes Acquisition of MacroGenics’ Rockville Manufacturing Operations

TAIPEI, TAIWAN - Media OutReach Newswire - 2 July 2026 - Bora Pharmaceuticals Co., Ltd. ("Bora" or "Bora Group"; TWSE: 6472; OTCQX: BORAY) today announced the completion of its acquisition of the GMP manufacturing operations of MacroGenics, Inc. (NASDAQ: MGNX) including its biologics drug substance facility in Rockville, Maryland and an associated warehousing center in Frederick, Maryland, for total consideration of US $122.5 million through its wholly owned subsidiary Bora Biologics USA, LLC.. Upon closing, Bora signed a long-term CDMO Service Agreement with MacroGenics.

Most Viewed

spot_img
WC26

World Cup 2026

Updates, Fixtures, Results & Standings